Non-Alcoholic Fatty Liver Disease (NAFLD) Detection Kit (ab273320)
Key features and details
- Assay type: Quantitative
- Detection method: Colorimetric/Fluorometric
- Platform: Microplate reader
- Sample type: Serum, Tissue
Overview
-
Product name
Non-Alcoholic Fatty Liver Disease (NAFLD) Detection Kit -
Detection method
Colorimetric/Fluorometric -
Sample type
Serum, Tissue -
Assay type
Quantitative -
Assay duration
Multiple steps standard assay -
Product overview
Non-Alcoholic Fatty Liver Disease (NAFLD) Detection Kit (ab273320) determines the alanine to pyruvate ratio in two independent enzymatic reactions. The difference between these two measurements gives the actual amount of alanine and pyruvate present in the samples. This kit provides a simple, fast and high throughput adaptable assay to measure the ratio of alanine and pyruvate with in various biological samples in both colorimetric (O.D. 570 nm) with detection range of alanine and pyruvate 2-10 nmol and fluorometric mode (Ex/Em = 535/587nm) with detection range 0.2-1 nmol.
-
Notes
Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses. -
Platform
Microplate reader
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 100 tests Alanine Converting Enzyme Mix (Lyophilized) 1 vial Alanine Standard (10 µmol) (Lyophilized) 1 vial Development Enzyme Mix (Lyophilized) 1 vial NAFLD Assay buffer 1 x 25ml NAFLD Substrate (Lyophilized) 1 vial Probe (in DMSO) 1 x 220µl Pyruvate Standard (100 mM) 1 x 100µl Sulfosalicylic acid (SSA) (Lyophilized) 1 unit -
Relevance
Non-Alcoholic Fatty Liver Disease (NAFLD; also known as Hepatosteatosis) is a disease caused by the accumulation of lipids in liver cells that is not related to alcohol usage. Recent studies on searching possible metabolic biomarkers for NAFLD, showed alanine to pyruvate ratio is significantly increased in rats that developed NAFLD. The result closely correlates with the increased activities of alanine aminotransferase, which is an established biomarker for liver damage.
Images
-
Flurorometric standard curve – Alanine.
Typical standard curve – data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.
-
Flurorometric standard curve – Pyruvate.Typical standard curve – data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.
-
Alanine/pyruvate ratio in deproteinized human serum and rat liver.Alanine/pyruvate ratio in deproteinized human serum (Pyruvate, DF= 1, 6 µL; Alanine, DF= 5, 6 µL) and rat liver (DF= 5; Pyruvate, 10 µL; Alanine, 2 µL) measured under fluorometric protocols. Assays were performed following the kit protocol.
-
Colorimetric standard curve – Alanine.Typical standard curve – data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.
-
Colorimetric standard curve – Pyruvate.Typical standard curve – data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.
